Evidence map›Paper›PMID 22044428›Full record

ArticleJournal of neurochemistry2012

Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions.

Sudarshana Purkayastha, Jason Ford, Baishali Kanjilal, Souleymane Diallo, Joseph Del Rosario Inigo, Lorenz Neuwirth, Abdeslem El Idrissi, Zaghloul Ahmed, Andrzej Wieraszko, Efrain C Azmitia and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neurochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. StandardizedAntioxidants (Basel, Switzerland) · 2020
    Article
  6. Article
  7. 5-HTThe Journal of physiology · 2019
    Article
  8. Article
  9. Repeated Clozapine Increases the Level of Serotonin 5-HTFrontiers in molecular neuroscience · 2018
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sudarshana PurkayasthaCSI/IBR Center for Developmental Neuroscience, The College of Staten Island, Staten Island, New York 10314, USA.
Jason Ford
Baishali Kanjilal
Souleymane Diallo
Joseph Del Rosario Inigo
Lorenz Neuwirth
Abdeslem El Idrissi
Zaghloul Ahmed
Andrzej Wieraszko
Efrain C Azmitia
Probal Banerjee
College of Staten Island · USNew York University · US

Funding

Regulation of ATPase II and Clearance of Cancer CellsR15CA077803 · NCI · COLLEGE OF STATEN ISLAND · PI BANERJEE, PROBAL · 1998 to 2004
$783k
The 5-HT1A Receptor and Brain DevelopmentR01MH071376 · NIMH · COLLEGE OF STATEN ISLAND · PI BANERJEE, PROBAL · 2006 to 2008
$711k
The 5-HT1A Receptor and Brain DevelopmentR56MH071376 · NIMH · COLLEGE OF STATEN ISLAND · PI BANERJEE, PROBAL · 2005 to 2005
$222k
NCI NIH HHS R15 CA077803NIMH NIH HHS MH071376-03NIMH NIH HHS R01 MH071376NIMH NIH HHS R56 MH071376
6 · The paper itself

Abstract

Aberrant dopamine release in the prefrontal cortex (PFC) is believed to underlie schizophrenia, but the mechanistic pathway through which a widely used antipsychotic, clozapine (Clz), evokes neurotransmitter-releasing electrical stimulation is unclear. We analyzed Clz-evoked regulation of neuronal activity in the PFC by stimulating axons in layers IV and V and recording the electrical effect in the post-synaptic pyramidal cells of layers II and III. We observed a Clz-evoked increase in population spike (PS), which was mediated by serotonin 1A receptor (5-HT(1A)-R), phospholipase Cβ, and Ca(2+)/calmodulin-dependent protein kinase II (CaMKII). Immunoblotting demonstrated that the Clz-activation of CaMKII was 5-HT(1A)-R-mediated. Intriguingly, the NMDA receptor (NMDA-R) antagonist (±)2-amino-5-phosphonovaleric acid (APV) eliminated the Clz-mediated increase in PS, suggesting that the 5-HT(1A)-R, NMDA-R and CaMKII form a synergistic triad, which boosts excitatory post-synaptic potential (EPSP), thereby enhancing PS. In corroboration, Clz as well as NMDA augmented field EPSP (fEPSP), and WAY100635 (a 5-HT(1A)-R antagonist), APV, and a CaMKII inhibitor eliminated this increase. As previously shown, CaMKII binds to the NMDA-R 2B (NR2B) subunit to become constitutively active, thereby inducing α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor recruitment to the post-synaptic membrane and an increase in fEPSP. Co-immunoprecipitation demonstrated that Clz potentiates interactions among CaMKII, NR2B, and 5-HT(1A)-R, possibly in the membrane rafts of the post-synaptic density (PSD), because pretreatment with methyl-β-cyclodextrin (MCD), an agent that disrupts rafts, inhibited both co-immunoprecipitation as well as fEPSP. In summary, Clz functions in the PFC by orchestrating a synergism among 5-HT(1A)-R, CaMKII, and NMDA-R, which augments excitability in the PFC neurons of layers II/III.

Indexed as

Action PotentialsAnimalsAnimals, NewbornCalcium-Calmodulin-Dependent Protein Kinase Type 2ClozapineDose-Response Relationship, DrugDrug InteractionsElectric StimulationEnzyme InhibitorsExcitatory Amino Acid AgentsGene Expression RegulationImmunoprecipitationIn Vitro TechniquesMaleMiceNeuronsCalcium-Calmodulin-Dependent Protein Kinase Type 2ClozapineEnzyme InhibitorsExcitatory Amino Acid AgentsReceptor, Serotonin, 5-HT1AReceptors, N-Methyl-D-AspartateSerotonin Agents

Identifiers

PMID22044428
PMCPMC3253201
OpenAlexW1540764326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.